Kenji Osafune

This inventor holds 18 USPTO granted patents and 17 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Stem Cell Differentiation. Top assignees: Kyoto University, Astellas Pharma Gmbh, Hokkaido University. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenji Osafune. Retrieved from https://idiyas.com/inventor/kenji-osafune

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 17)

% Patents Active = 83.3

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 21)

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 16(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Bile Duct Chip

Renal Progenitor Cells

Stem Cell Differentiation

Pharmaceutical Composition

Polycystic Kidney Disease

Ureteric Bud Cells

Mesodermal-Lineage

Erythropoietin-Producing Cells

Pancreatic Bud Cells

Alveolar Epithelial Progenitor Cells

Hepatocytes

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735663 - BILE DUCT CHIP AND USE THEREOF (2026-09-15),

2. 12697314 - Pharmaceutical composition for treating autosomal dominant polycystic kidney disease (2026-08-04),

3. 12674144 - Method of producing a mesodermal-lineage primitive streak cell (2026-07-07),

4. 12577536 - Method for isolating ureteric bud tip cells (2026-03-17),

5. 12565640 - Method for inducing ureteric bud-like tissue (2026-03-03),

6. 12514834 - PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY (2026-01-06),

7. 11821007 - Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell (2023-11-21),

8. 11746332 - Method for producing renal progenitor cells (2023-09-05),

9. 11225642 - Method for producing renal progenitor cells (2022-01-18),

10. 10961508 - Method for inducing alveolar epithelial progenitor cells (2021-03-30),

11. 10731133 - Method for producing renal progenitor cells (2020-08-04),

12. 10711249 - Method for inducing hepatocytes (2020-07-14),

13. 10472610 - Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells (2019-11-12),

14. 9902938 - Method for inducing exocrine pancreatic cells (2018-02-27),

15. 9890357 - Method for inducing differentiation of human pluripotent stem cells into intermediate mesoderm cells (2018-02-13),

Title: Innovator Kenji Osafune: Pioneering Advances in Renal Progenitor Cell Research

Introduction

Kenji Osafune is a renowned inventor based in Kyoto, Japan, known for his groundbreaking contributions in the field of regenerative medicine. With an impressive portfolio of 12 patents, Osafune's research focuses primarily on the differentiation of pluripotent stem cells into renal progenitor cells, which holds significant potential for treating renal diseases.

Latest Patents

Two of Kenji Osafune's latest patents include innovative methods for inducing the differentiation of both intermediate mesodermal cells and pluripotent stem cells to renal progenitor cells. The first method outlines a detailed protocol involving the culture of pluripotent stem cells in mediums enriched with FGF2, BMP4, a GSK-3β inhibitor, and retinoic acid or its derivatives. This process enables the subsequent cultivation of these cells in different media formations, ultimately leading to the successful production of renal progenitor cells from intermediate mesodermal cells. The second patent describes methods to acquire high-purity renal progenitor cells, targeting specific cell surface antigens to refine the cell population. These advancements are crucial for the future of regenerative treatments for conditions like renal failure.

Career Highlights

Kenji Osafune has made noteworthy strides during his academic and professional career, particularly while collaborating with institutions like Kyoto University and Astellas Pharma GmbH. His commitment to enhancing stem cell research continues to pave the way for innovative therapies that directly address kidney health challenges.

Collaborations

Throughout his journey, Osafune has had the opportunity to work alongside esteemed colleagues such as Yukiko Yamagishi and Taro Toyoda. These collaborations enrich his research and contribute to the collective advancement of knowledge in the field of regenerative medicine.

Conclusion

Kenji Osafune's trailblazing work in the realm of renal progenitor cell differentiation underscores his commitment to innovation within medical science. As he continues to develop novel methods and refine existing techniques, his contributions promise to significantly impact the landscape of medical treatments for renal diseases and beyond.

Profile summary based on public USPTO records.